Profile data is unavailable for this security.
About the company
PT Kalbe Farma Tbk is an Indonesia-based company, which is engaged in the development, manufacturing and trading of pharmaceutical products, including human medicines and consumer health products. Its business divisions include Prescription Pharmaceutical, Consumer Health Division, Nutritional, and Distribution and Logistic divisions. The Prescription Pharmaceuticals division provides a range of products for all groups, from unbranded generic drugs for the mass-market segment, to branded generics and licensed drugs. The Consumer Health division's product portfolio spans from over-the-counter (OTC) drugs and energy drinks to a selection of ready-to-drink healthy beverage products. The Nutritional division manages a range of nutritional products, comprising powdered milk products for all age segments. It also offers a selection of non-milk nutritional products. The Distribution and Logistics Division operates the distribution coverage for pharmaceuticals products in Indonesia.
- Revenue in IDR (TTM)34.38tn
- Net income in IDR3.49tn
- Incorporated1967
- Employees12.78k
- LocationKalbe Farma Tbk PTGedung KALBE Let.Jend Suprato Kav. 4JAKARTA PUSAT 10510IndonesiaIDN
- Phone+62 2 142873888
- Fax+62 214256326
- Websitehttps://www.kalbe.co.id
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Liquidia Corp | 1.17tn | -2.05tn | 46.60tn | 157.00 | -- | 125.12 | -- | 39.94 | -1.43 | -1.43 | 0.8101 | 0.2540 | 0.2618 | 0.6138 | 3.45 | 440,866.30 | -46.08 | -58.31 | -62.15 | -66.89 | 89.11 | 75.60 | -176.04 | -564.24 | 1.96 | -7.36 | 0.8972 | -- | -19.97 | 11.64 | -66.10 | -- | 35.49 | -- |
| Shanghai Henlius Biotech Inc | 14.23tn | 2.02tn | 47.83tn | 3.54k | 37.13 | 8.98 | 15.63 | 3.36 | 1.72 | 1.72 | 12.12 | 7.13 | 0.5386 | 1.73 | 5.86 | 1,874,475.00 | 7.66 | -3.21 | 13.85 | -5.76 | 75.77 | 72.50 | 14.22 | -7.87 | 0.5046 | 10.47 | 0.5185 | -- | 6.11 | 128.98 | 50.26 | -- | 10.83 | -- |
| Twist Bioscience Corp | 6.60tn | -1.29tn | 48.21tn | 979.00 | -- | 6.27 | -- | 7.30 | -1.27 | -1.27 | 6.46 | 7.44 | 0.6282 | 6.71 | 8.76 | 399,956.10 | -12.29 | -24.09 | -13.97 | -26.80 | 51.62 | 43.29 | -19.56 | -67.76 | 3.37 | -- | 0.00 | -- | 20.32 | 33.11 | 62.79 | -- | 23.20 | -- |
| Kalbe Farma Tbk PT | 34.38tn | 3.49tn | 48.45tn | 12.78k | 13.51 | 2.04 | 11.10 | 1.41 | 76.62 | 76.62 | 754.10 | 507.01 | 1.17 | 3.08 | 6.47 | 2,664,288,000.00 | 12.05 | 12.17 | 15.24 | 15.15 | 39.50 | 40.06 | 10.31 | 10.97 | 2.36 | -- | 0.0206 | 52.79 | 7.16 | 7.59 | 17.13 | 5.27 | -8.81 | 12.47 |
| Hisamitsu Pharmaceutical Co Inc | 17.02tn | 2.14tn | 48.71tn | 2.80k | 21.90 | 1.58 | 16.56 | 2.86 | 276.99 | 276.99 | 2,208.13 | 3,837.32 | 0.4704 | 2.64 | 3.42 | 56,901,390.00 | 6.04 | 4.34 | 7.25 | 4.99 | 59.05 | 57.83 | 12.84 | 10.32 | 3.28 | -- | 0.0086 | 50.29 | 10.09 | 2.04 | 55.76 | 3.08 | 29.89 | 0.7127 |
| Catalyst Pharmaceuticals Inc | 9.93tn | 3.61tn | 49.24tn | 182.00 | 14.20 | 3.07 | 11.58 | 4.96 | 1.68 | 1.68 | 4.63 | 7.79 | 0.6024 | 3.08 | 6.14 | 3,236,203.00 | 21.92 | 22.15 | 25.40 | 25.81 | 85.19 | 85.59 | 36.39 | 31.20 | 5.82 | -- | 0.00 | 0.00 | 19.78 | 37.68 | 30.78 | 23.37 | 38.45 | -- |
| Hypera SA | 22.27tn | 2.64tn | 49.24tn | 9.00k | 17.10 | 1.14 | 13.77 | 2.21 | 1.28 | 1.28 | 10.85 | 19.16 | 0.2733 | 1.49 | 3.04 | -- | 3.22 | 7.37 | 3.98 | 8.92 | 56.70 | 62.47 | 11.77 | 23.17 | 0.8382 | -- | 0.4327 | 49.00 | -5.97 | 17.70 | -18.53 | 2.47 | 16.39 | 1.77 |
| Arcutis Biotherapeutics Inc | 6.34tn | -272.06bn | 49.34tn | 354.00 | -- | 15.36 | -- | 7.78 | -0.1325 | -0.1325 | 2.93 | 1.54 | 0.962 | 1.97 | 3.43 | 1,062,350.00 | -4.13 | -48.93 | -5.65 | -57.14 | 90.24 | -- | -4.29 | -147.21 | 2.99 | -3.84 | 0.3651 | -- | 91.34 | -- | 88.47 | -- | 101.59 | -- |
| Suzhou Zelgen Biopharmaceuticals Co Ltd | 1.81tn | -325.72bn | 49.50tn | 910.00 | -- | 17.64 | -- | 27.30 | -0.5038 | -0.5038 | 2.80 | 4.34 | 0.2482 | 0.446 | 4.77 | 815,689.40 | -4.56 | -17.15 | -8.23 | -25.89 | 89.95 | 93.14 | -18.36 | -118.33 | 1.72 | -- | 0.4949 | -- | 37.91 | -- | 50.52 | -- | 44.66 | -- |
| Joincare Pharmaceutical Group Ind. Co. | 37.13tn | 3.34tn | 49.60tn | 14.35k | 14.97 | 1.37 | -- | 1.34 | 0.7413 | 0.7413 | 8.24 | 8.13 | 0.4211 | 2.40 | 5.51 | 1,059,126.00 | 8.29 | 8.60 | 17.45 | 18.66 | 61.28 | 62.42 | 19.70 | 17.66 | 2.38 | -- | 0.1776 | 27.59 | -6.17 | 5.45 | -3.90 | 9.17 | 6.84 | 4.56 |
| Emcure Pharmaceuticals Ltd | 16.21tn | 1.59tn | 50.17tn | 6.73k | 31.48 | -- | 21.07 | 3.10 | 45.91 | 45.91 | 467.02 | -- | -- | -- | -- | 13,148,240.00 | -- | 8.47 | -- | 15.86 | 59.93 | 59.30 | 10.11 | 8.99 | -- | 30.68 | -- | 0.00 | 18.59 | 9.36 | 36.76 | 52.13 | 21.35 | -- |
| Almirall SA | 21.69tn | 903.52bn | 50.54tn | 2.11k | 55.71 | 1.74 | 34.80 | 2.33 | 0.2158 | 0.2158 | 5.15 | 6.92 | 0.4682 | 1.35 | 8.44 | 525,656.60 | 1.95 | -0.1648 | 2.29 | -0.1933 | 78.66 | 78.17 | 4.17 | -0.4008 | 1.53 | -- | 0.1874 | -- | 12.41 | 6.54 | 354.85 | -9.08 | 12.40 | -- |
| Sunshine Lake Pharma Co Ltd | 8.28tn | -971.72bn | 51.65tn | 6.53k | -- | 53.86 | 19,929.87 | 6.24 | -0.7803 | -0.7803 | 6.65 | 0.7709 | -- | -- | -- | 585,492.90 | -- | -- | -- | -- | 73.62 | -- | -12.86 | -- | 0.7739 | -0.7591 | 0.5111 | -- | -37.06 | -- | -212.17 | -- | -- | -- |
Data as of Mar 04 2026. Currency figures normalised to Kalbe Farma Tbk PT's reporting currency: Indonesian Rupiah IDR
6.30%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 04 Feb 2026 | 725.89m | 1.55% |
| Norges Bank Investment Managementas of 30 Jun 2025 | 586.26m | 1.25% |
| Swedbank Robur Fonder ABas of 30 Jan 2026 | 455.00m | 0.97% |
| BlackRock Fund Advisorsas of 06 Feb 2026 | 316.42m | 0.68% |
| MFS International Singapore Pte Ltd.as of 31 Jan 2026 | 260.02m | 0.56% |
| PT Schroder Investment Management Indonesiaas of 31 Dec 2024 | 197.34m | 0.42% |
| Dimensional Fund Advisors LPas of 05 Feb 2026 | 115.89m | 0.25% |
| First Sentier Investors (UK) IM Ltd.as of 31 Jan 2026 | 106.90m | 0.23% |
| Geode Capital Management LLCas of 06 Feb 2026 | 98.84m | 0.21% |
| BlackRock Advisors (UK) Ltd.as of 06 Feb 2026 | 86.21m | 0.18% |
More ▼
Data from 31 Dec 2024 - 31 Dec 2025Source: FactSet Research Systems Inc.
